While various causes have been documented, in one study, 14% of HES patients exhibited a Fip1-like 1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA) fusion gene, due to a deletion in chromosome 4q12, responding very well to low-dose imatinib [5]. Here, FIP1L1 is linked to hypereosinophilic syndrome.